newsfilter
← Latest News
GlobeNewswire·

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the